David L. Bajor

3.6k total citations
76 papers, 1.7k citations indexed

About

David L. Bajor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, David L. Bajor has authored 76 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in David L. Bajor's work include Pancreatic and Hepatic Oncology Research (21 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). David L. Bajor is often cited by papers focused on Pancreatic and Hepatic Oncology Research (21 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). David L. Bajor collaborates with scholars based in United States, France and Spain. David L. Bajor's co-authors include Robert H. Vonderheide, Rebecca A. Evans, Rafael Winograd, Katelyn T. Byrne, Ben Z. Stanger, E. John Wherry, Anders R.L. Meyer, Emma E. Furth, Cynthia Clendenin and Pamela M. Odorizzi and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

David L. Bajor

68 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David L. Bajor United States	18	1.3k	988	289	179	133	76	1.7k
Charles G. Rickert United States	12	922 0.7×	830 0.8×	370 1.3×	167 0.9×	124 0.9×	24	1.4k
Julian A. Marin‐Acevedo United States	13	1.1k 0.9×	732 0.7×	354 1.2×	151 0.8×	81 0.6×	27	1.7k
Alex Chehrazi‐Raffle United States	11	869 0.7×	461 0.5×	374 1.3×	171 1.0×	138 1.0×	64	1.3k
Gina Mantia-Smaldone United States	19	751 0.6×	492 0.5×	487 1.7×	193 1.1×	271 2.0×	56	1.8k
Margaret E. Gatti‐Mays United States	16	746 0.6×	539 0.5×	306 1.1×	137 0.8×	72 0.5×	74	1.1k
Fabio Conforti Italy	18	1.2k 0.9×	390 0.4×	398 1.4×	197 1.1×	133 1.0×	78	1.9k
Diana Miao United States	12	952 0.7×	715 0.7×	769 2.7×	254 1.4×	100 0.8×	23	1.7k
Teresa M. Petrella Canada	19	973 0.8×	361 0.4×	390 1.3×	94 0.5×	103 0.8×	62	1.3k
Peter A. Prieto United States	13	828 0.6×	659 0.7×	233 0.8×	51 0.3×	89 0.7×	43	1.1k
Raju Vaddepally United States	5	745 0.6×	352 0.4×	202 0.7×	108 0.6×	69 0.5×	10	997

Countries citing papers authored by David L. Bajor

Since Specialization

Citations

This map shows the geographic impact of David L. Bajor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Bajor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Bajor more than expected).

Fields of papers citing papers by David L. Bajor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Bajor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Bajor. The network helps show where David L. Bajor may publish in the future.

Co-authorship network of co-authors of David L. Bajor

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Bajor. A scholar is included among the top collaborators of David L. Bajor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Bajor. David L. Bajor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naing, Aung, Amit Mahipal, Milind Javle, et al.. (2025). Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study. PubMed. 8(1). 71–81.

Strickler, John H., Andrea Cercek, Salvatore Siena, et al.. (2024). Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).. Journal of Clinical Oncology. 42(16_suppl). 3509–3509. 2 indexed citations

Sahai, Vaibhav, Kent A. Griffith, David B. Zhen, et al.. (2024). Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).. Journal of Clinical Oncology. 42(16_suppl). 4116–4116. 2 indexed citations

Selfridge, J. Eva, Christopher L. Hallemeier, Krishan R. Jethwa, et al.. (2024). Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer. Cancers. 16(13). 2407–2407. 1 indexed citations

Chakrabarti, Sakti, Emily Steinhagen, Ahmed A. Mohamed, et al.. (2023). P-219 Non-operative management of localized mismatch repair deficient colon cancer: A real-world perspective. Annals of Oncology. 34. S93–S93. 1 indexed citations

Elshami, Mohamedraed, Richard S. Hoehn, John B. Ammori, et al.. (2023). Differences in the surgical management of early-stage hepatocellular carcinoma at minority versus non-minority-serving hospitals. Surgery. 174(5). 1201–1207. 1 indexed citations

Ahmed, Faruque, David L. Bajor, Ahmed A. Mohamed, et al.. (2023). SO-19 The outcome of resected stage II colon cancer patients with deficient mismatch repair T4 tumors: A National Cancer Database analysis. Annals of Oncology. 34. S170–S170. 1 indexed citations

Pitts, Stephanie Jilcott, Amit Mahipal, David L. Bajor, & Amr Mohamed. (2023). Hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumors (PTHrP-PNETs): Case Report. Frontiers in Oncology. 13. 1197288–1197288. 2 indexed citations

Elshami, Mohamedraed, John B. Ammori, Jeffrey M. Hardacre, et al.. (2023). Surgical Resection Alone is Associated With Higher Long-Term Survival Than Multiagent Chemotherapy Alone for Patients With Localized Biliary Tract Cancers. Journal of Surgical Research. 295. 705–716.

10.

Chung, Michelle, David L. Bajor, Amr Mohamed, et al.. (2023). Circulating tumor DNA (ctDNA) dynamics in response to checkpoint inhibitor immunotherapy in colorectal cancer.. Journal of Clinical Oncology. 41(16_suppl). e15540–e15540.

11.

Lee, Zhenghong, Sree Harsha Tirumani, Qiubai Li, et al.. (2023). The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience. Journal of Gastrointestinal Oncology. 14(2). 1087–1094. 4 indexed citations

12.

Davar, Diwakar, Roberta Zappasodi, Hong Wang, et al.. (2022). Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(18). 3990–4002. 37 indexed citations

13.

Mohamed, Amr, Asfar S. Azmi, L. Sylvia, et al.. (2022). Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination. Current Oncology. 29(11). 9018–9030. 2 indexed citations

14.

Mohamed, Amr, Mohamed E. Hamid, Amit Mahipal, et al.. (2022). Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines. Cancers. 15(1). 295–295. 28 indexed citations

15.

Elshami, Mohamedraed, Jonathan J. Hue, Richard S. Hoehn, et al.. (2022). Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies. Surgery. 173(2). 289–298. 3 indexed citations

16.

Elshami, Mohamedraed, Jonathan J. Hue, Richard S. Hoehn, et al.. (2022). A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment. HPB. 24(8). 1280–1290. 7 indexed citations

17.

Hue, Jonathan J., Erryk Katayama, Sarah C. Markt, et al.. (2021). A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Surgery. 172(1). 257–264. 11 indexed citations

18.

Aiello, Nicole M., David L. Bajor, Robert J. Norgard, et al.. (2016). Metastatic progression is associated with dynamic changes in the local microenvironment. Nature Communications. 7(1). 12819–12819. 95 indexed citations

19.

Winograd, Rafael, Katelyn T. Byrne, Rebecca A. Evans, et al.. (2015). Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunology Research. 3(4). 399–411. 345 indexed citations

20.

Vonderheide, Robert H., Keith T. Flaherty, Magi Khalil, et al.. (2007). Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody. Journal of Clinical Oncology. 25(7). 876–883. 416 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact